GleamWall
中文EN

XCUR EXICURE, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1698530 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-97.7%
TTM net income YoY-235.0%
TTM EPS YoY65.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,228.2%
Net margin-801.4%
FCF margin—
EBITDA margin-1,222.6%

Returns

ROE-132.6%
ROA-34.0%
ROIC (approx.)-326.7%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets85.5%
Debt / equity0.00x
Current ratio0.71x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$500,000
R&D expense$3.29M$0
SG&A expense$6.83M$5.45M
Operating income-$4.23M-$12.23M
Interest expense$1,000$18,000
Pretax income-$5.58M-$9.69M
Income tax-$634,000$8,000
Net income-$4.95M-$9.70M
EBITDA-$3.99M-$12.20M
EPS (basic)-0.79-4.75
EPS (diluted)-0.79-4.75
Weighted avg. shares (diluted)6.30M2.04M
Balance sheet
Cash & equivalents$3.75M$12.51M
Current assets$4.62M$13.67M
PP&E, net$306,000$26,000
Goodwill$4.40M$0
Intangibles$3.78M$0
Total assets$14.04M$15.06M
Current liabilities$3.89M$3.07M
Total liabilities$10.12M$8.28M
Shareholders' equity$3.93M$6.77M
Shares outstanding6.37M6.03M
Cash flow statement
Operating cash flow-$8.55M-$2.91M
Capital expenditure$1,000$0
Free cash flow-$8.56M-$2.91M
Investing cash flow-$1.81M$0
Financing cash flow$1.60M$13.40M
Depreciation & amortization$242,000$28,000
Stock-based compensation$2,000$22,000

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.